Shelton Capital Management’s Emergent Biosolutions EBS Stock Holding History

Shelton Capital Management’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-3,143	Closed	-$249K	–	772
2020 Q2	$249K	Buy	+3,143	New	+$234K	0.01%	512
2020 Q1	–	Sell	-3,922	Closed	-$212K	–	703
2019 Q4	$212K	Sell	3,922 -514	-12%	-$27.9K	0.01%	730
2019 Q3	$232K	Hold	4,436	–	–	0.01%	671
2019 Q2	$214K	Buy	4,436 +4,212	+1,880%	+$202K	0.01%	742
2019 Q1	$4.44K	Sell	224 -4,212	-95%	-$248K	0.02%	607
2018 Q4	$263K	Buy	4,436 +887	+25%	+$57.2K	0.02%	537
2018 Q3	$234K	Buy	+3,549	New	+$207K	0.01%	752

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

SCM

Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return

Shelton Capital Management's EBS Position: Q3 2020 in Review

Shelton Capital Management sold out of Emergent Biosolutions (EBS) in Q3 2020, closing a stake of 3,143 shares — an estimated $249K sold.

Shelton Capital Management first reported a position in EBS in Q3 2018 and held it in 7 quarters. The position peaked at $263K in Q4 2018. 358 funds tracked by Wall St. Rank hold EBS as of Q3 2020.

Shelton Capital Management reported no remaining Emergent Biosolutions position as of Q3 2020 after selling out during the quarter.
Shelton Capital Management sold 3,143 Emergent Biosolutions shares in Q3 2020, an estimated $249K.
Shelton Capital Management first reported a position in Emergent Biosolutions in Q3 2018 and held it in 7 quarters.
Shelton Capital Management's Emergent Biosolutions position peaked at $263K in Q4 2018.
358 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q3 2020.

Based on Shelton Capital Management's 13F filing for Q3 2020, filed 9 Nov 2020.